The Cancer Letter

Inside information on cancer research and drug development

Vol.
31
No.
3
January 21, 2005Jan 21, 2005
Free
DOWNLOAD THE PDF

FDA Plans to Discuss the Negative Trial of AstraZeneca’s Drug Iressa With the Oncologic Drugs Advisory Committee in March.

Also in this 8-page Issue: Safety Warnings Are Added to Labels for Epo and Avastin.

Cancer Accounts for 23% of U.S. Deaths, American Cancer Society Says.

NCI Sets its Targets for Grant Success Rate and R01 Payline for FY05.

NIH Panel Calls for Further Research On End-of-Life Issues.

NAS Committee Urges Greater Rewards For Interdisciplinary Research.

CAM Therapies Should Be Held to Conventional Standards and Congress Should Toughen Dietary Supplements Act, IOM Panel Says.

Funding Opportunities Listed.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account